A multiple ascending dose study of GR3027 for the treatment of Hepatic Encephalopathy
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs GR 3027 (Primary)
- Indications Hepatic encephalopathy
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2017 According to a Karolinska Development media release, phase 1b portion of this trial is completed.
- 13 Sep 2017 According to a Karolinska Development media release, results of phase 2a portion expected during 2018 .
- 13 Sep 2017 Results from Phase Ib portion (n=18) published in the Karolinska Development Media Release